For this reason, RCTs are important to conduct in patients from various backgrounds and stroke severity to determine the optimum dose of tPA. Healthcare professionals need to remain cautious in clinical practice when considering low-dose tPA treatment of acute ischemic patients. The gene discussed is PLAT; the disease is stroke disorder.